
Conference Coverage
Latest Content

Podcast: NIH Team Details Path From Ketamine Metabolite Discovery to Phase 2 Trials

sNDA Submitted: Caplyta for the Treatment of Bipolar Mania

Why Depression Subtypes Matter: Lessons From 25 Years in the Clinic

2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD

Phase 3 Data Back Tau PET Agent Florquinitau F 18 for Detecting Neurofibrillary Tangles in Alzheimer Disease

Shorts










Digital Edition
Continuing Medical Education
All News

Clinicians weigh ketamine vs FDA-approved esketamine for TRD, with evolving guidance on dosing, safety monitoring, and long-term maintenance decisions.

Review news from the last week in pharmacology, legislation, and research.

Hormone shifts during menstruation, pregnancy, and menopause can trigger depression in susceptible women, highlighting connected brain pathways and guiding targeted, stabilizing treatments.

HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as day 2.

The FDA has approved dexmedetomidine (Igalmi) sublingual film for at-home use.

A critical care physician explains why quiet, hypoactive ICU delirium is often missed and why its effects follow patients long after discharge.

Many traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.

Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.

Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.

Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.

Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.

The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.

Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.

Explore the types of scams encountered in psychiatric practice in order to help identify those at risk.

















































